Patents by Inventor Katja Fink
Katja Fink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059757Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.Type: ApplicationFiled: April 14, 2021Publication date: February 22, 2024Inventors: Martina BELTRAMELLO, Siro BIANCHI, Elisabetta CAMERONI, Davide CORTI, Nadine CZUDNOCHOWSKI, Katja FINK, Florian A. LEMPP, Dora PINTO, Matteo Samuele PIZZUTO, Gyorgy SNELL, Amalio TELENTI, Fabrizia ZATTA
-
Patent number: 11891432Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.Type: GrantFiled: March 15, 2019Date of Patent: February 6, 2024Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology & ResearchInventors: Katja Fink, Cheng-I Wang, Lisa Fong Poh Ng, Laurent Renia, Zenjiro Sampei, Xing'er Christine Xoo
-
Publication number: 20240018219Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding the anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.Type: ApplicationFiled: August 22, 2023Publication date: January 18, 2024Inventors: Zenjiro SAMPEI, Xing'er Christine KOO, Katja FINK, Roland ZUEST
-
Publication number: 20230331821Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: September 14, 2022Publication date: October 19, 2023Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Patent number: 11780908Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.Type: GrantFiled: October 8, 2020Date of Patent: October 10, 2023Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and ResearchInventors: Zenjiro Sampei, Xing'er Christine Koo, Katja Fink, Roland Zuest
-
Publication number: 20230084102Abstract: The present invention provides antibodies targeting Plasmodium sporozoites, in particular plasmodium circumsporozoite protein. The invention also provides nucleic acids that encode such antibodies. In addition, the invention provides the use of the antibodies of the invention in prophylaxis and treatment malaria.Type: ApplicationFiled: April 30, 2020Publication date: March 16, 2023Inventors: Davide CORTI, Luca PICCOLI, Katja FINK, Elisabetta CAMERONI
-
Patent number: 11499157Abstract: The present invention generally relates to specific immune-modulatory RNA species that have a small hairpin structure (shRNA), and that can bind to retinoic acid inducible gene I receptor (RIG-I). In particular, said RNA species comprise a nucleotide insertion to create a kink in the stem region. Also encompassed are compositions comprising such shRNA, for use as antiviral or anticancer medication, or as adjuvants in vaccine.Type: GrantFiled: January 17, 2019Date of Patent: November 15, 2022Assignees: Nanyang Technological University, Agency for Science, Technology and ResearchInventors: Dahai Luo, Katja Fink, Hui Yee Yong, Chin Yong Victor Ho
-
Patent number: 11479599Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: GrantFiled: July 23, 2021Date of Patent: October 25, 2022Assignee: Vir Biotechnology, Inc.Inventors: Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
-
Publication number: 20210371504Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: July 23, 2021Publication date: December 2, 2021Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Patent number: 11168128Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: GrantFiled: February 25, 2021Date of Patent: November 9, 2021Assignee: VIR BIOTECHNOLOGY, INC.Inventors: Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
-
Publication number: 20210261650Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: February 25, 2021Publication date: August 26, 2021Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Publication number: 20210095008Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.Type: ApplicationFiled: October 8, 2020Publication date: April 1, 2021Inventors: Zenjiro SAMPEI, Xing'er Christine KOO, Katja FINK, Roland ZUEST
-
Publication number: 20210017256Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.Type: ApplicationFiled: March 15, 2019Publication date: January 21, 2021Applicants: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology & ResearchInventors: Katja FINK, Cheng-I WANG, Lisa Fong Poh NG, Laurent RENIA, Zenjiro SAMPEI, Xing'er Christine XOO
-
Publication number: 20210000856Abstract: The present invention generally relates to specific immune-modulatory RNA species that have a small hairpin structure (shRNA), and that can bind to retinoic acid inducible gene I receptor (RIG-I). In particular, said RNA species comprise a nucleotide insertion to create a kink in the stem region. Also encompassed are compositions comprising such shRNA, for use as antiviral or anticancer medication, or as adjuvants in vaccine.Type: ApplicationFiled: January 17, 2019Publication date: January 7, 2021Inventors: Dahai Luo, Katja Fink, Hui Yee Yong, Chin Yong Victor Ho
-
Patent number: 10844113Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.Type: GrantFiled: June 10, 2019Date of Patent: November 24, 2020Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and ResearchInventors: Zenjiro Sampei, Xing'er Christine Koo, Katja Fink, Roland Zuest
-
Patent number: 10604561Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.Type: GrantFiled: September 15, 2017Date of Patent: March 31, 2020Assignees: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and ResearchInventors: Zenjiro Sampei, Xing'er Christine Koo, Katja Fink, Roland Zuest
-
Publication number: 20190315840Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in Sa parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1q-binding activity when compared to the parent Fc region.Type: ApplicationFiled: June 10, 2019Publication date: October 17, 2019Inventors: Zenjiro SAMPEI, Xing'er Christine KOO, Katja FINK, Roland ZUEST
-
Publication number: 20190218277Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1q-binding activity when compared to the parent Fc region.Type: ApplicationFiled: September 15, 2017Publication date: July 18, 2019Inventors: Zenjiro SAMPEI, Xing'er Christine KOO, Katja FINK, Roland ZUEST
-
Patent number: 10316078Abstract: Disclosed are isolated antibodies, or antigen binding fragments thereof, that bind to dengue virus epitopes, as well as kits containing them, compositions containing them, and passive vaccines comprising them, in one embodiment, the antibody or antigen binding fragment thereof is capable of binding to a whole dengue virus particle better than binding to a dengue virus surface glycoprotein. Also disclosed are methods of using the antibodies or antigen binding fragments thereof, nucleic acids encoding them, vectors expressing the nucleic acids, host producing them, and methods of manufacturing them.Type: GrantFiled: March 17, 2016Date of Patent: June 11, 2019Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, NATIONAL UNIVERSITY OF SINGAPOREInventors: Cheng-I Wang, Katja Fink, Paul Macary, Roland Zuest, Meihui Xu
-
Publication number: 20180072798Abstract: Disclosed are isolated antibodies, or antigen binding fragments thereof, that bind to dengue virus epitopes, as well as kits containing them, compositions containing them, and passive vaccines comprising them, in one embodiment, the antibody or antigen binding fragment thereof is capable of binding to a whole dengue virus particle better than binding to a dengue virus surface glycoprotein. Also disclosed are methods of using the antibodies or antigen binding fragments thereof, nucleic acids encoding them, vectors expressing the nucleic acids, host producing them, and methods of manufacturing them.Type: ApplicationFiled: March 17, 2016Publication date: March 15, 2018Applicants: National University of Singapore, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Cheng-I WANG, Katja FINK, Paul MACARY, Roland ZUEST, Meihui XU